NIVOLUMAB Pharmacologic Class Indexing
- Class set ID
- 95ae80e3-1172-4efd-810e-d5ef9b35d0bf
- Version
- 2
- Effective date
- 20180813
- Type
- Indexing - Pharmacologic Class
Mapped DailyMed Labels#
| Label | Manufacturer | Effective | SPL version |
|---|---|---|---|
| These highlights do not include all the information needed to use OPDIVO QVANTIG safely and effectively. See full prescribing information for OPDIVO QVANTIG. OPDIVO QVANTIG™ (nivolumab and hyaluronidase-nvhy) injection, for subcutaneous use. Initial U.S. Approval: 2024 | E.R. Squibb & Sons, L.L.C. | Bioreliance Ltd. | 20260512 | 8 |
| These highlights do not include all the information needed to use OPDIVO safely and effectively. See full prescribing information for OPDIVO. OPDIVO ® (nivolumab) injection, for intravenous use Initial U.S. Approval: 2014 | E.R. Squibb & Sons, L.L.C. | 20260512 | 67 |
| These highlights do not include all the information needed to use OPDUALAG safely and effectively. See full prescribing information for OPDUALAG. OPDUALAG™ (nivolumab and relatlimab-rmbw) injection, for intravenous use Initial U.S. Approval: 2022 | E.R. Squibb & Sons, L.L.C. | 20240301 | 2 |